Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
IST:MEDTR'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -0.32 Med: 16.05 Max: 42.71
Current: 0.63
During the past 8 years, MEDITERA TIBBI MALZEMENAYI VE TICARET AS's highest Return-on-Tangible-Equity was 42.71%. The lowest was -0.32%. And the median was 16.05%.
IST:MEDTR's Return-on-Tangible-Equity is ranked worse than 57.58% of 759
companies
in the Medical Devices & Instruments industry
Industry Median: 4.04
vs IST:MEDTR: 0.63
MEDITERA TIBBI MALZEMENAYI VE TICARET AS (IST:MEDTR) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
MEDITERA TIBBI MALZEMENAYI VE TICARET AS Return-on-Tangible-Equity Related Terms
MEDITERA TIBBI MALZEMENAYI VE TICARET AS Return-on-Tangible-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEDITERA TIBBI MALZEMENAYI VE TICARET AS Return-on-Tangible-Equity Chart
MEDITERA TIBBI MALZEMENAYI VE TICARET AS Annual Data
IST:MEDTR vs ABT, SYK, MDT: Return-on-Tangible-Equity Comparison
For the Medical Devices subindustry, MEDITERA TIBBI MALZEMENAYI VE TICARET AS's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MEDITERA TIBBI MALZEMENAYI VE TICARET AS Return-on-Tangible-Equity vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, MEDITERA TIBBI MALZEMENAYI VE TICARET AS's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where MEDITERA TIBBI MALZEMENAYI VE TICARET AS's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of -7.47% mean?
MEDITERA TIBBI MALZEMENAYI VE TICARET AS (IST:MEDTR) has a Return-on-Tangible-Equity of -7.47% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on MEDITERA TIBBI MALZEMENAYI VE TICARET AS and its competitors. According to the industry distribution chart, MEDITERA TIBBI MALZEMENAYI VE TICARET AS ranks #437 out of 759 companies in the Medical Devices & Instruments industry, placing it in the top 57.6%.
Is MEDITERA TIBBI MALZEMENAYI VE TICARET AS's Return-on-Tangible-Equity too high?
MEDITERA TIBBI MALZEMENAYI VE TICARET AS's current Return-on-Tangible-Equity is -7.47%. Based on the distribution chart, MEDITERA TIBBI MALZEMENAYI VE TICARET AS ranks #437 out of 759 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, MEDITERA TIBBI MALZEMENAYI VE TICARET AS has a GF Score™ of 79/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does MEDITERA TIBBI MALZEMENAYI VE TICARET AS's Return-on-Tangible-Equity compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, MEDITERA TIBBI MALZEMENAYI VE TICARET AS ranks #437 out of 759 companies for Return-on-Tangible-Equity. This places MEDITERA TIBBI MALZEMENAYI VE TICARET AS in the lower half of its industry. The industry median Return-on-Tangible-Equity is 4.04. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Medical Devices & Instruments company?
The median Return-on-Tangible-Equity among Medical Devices & Instruments companies is 4.04, based on 759 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on MEDITERA TIBBI MALZEMENAYI VE TICARET AS and its competitors. For the Medical Devices & Instruments industry, the median Return-on-Tangible-Equity is 4.04 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. MEDITERA TIBBI MALZEMENAYI VE TICARET AS's current Return-on-Tangible-Equity is -7.47%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MEDITERA TIBBI MALZEMENAYI VE TICARET AS stock overvalued right now?
Based on GuruFocus' analysis, MEDITERA TIBBI MALZEMENAYI VE TICARET AS (IST:MEDTR) is currently considered Significantly Undervalued. The stock's GF Value™ is ₺43.90, compared to a current price of ₺27.32 — trading 37.8% below its estimated fair value. The current Return-on-Tangible-Equity is -7.47%. MEDITERA TIBBI MALZEMENAYI VE TICARET AS's overall GF Score™ is 79/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For MEDITERA TIBBI MALZEMENAYI VE TICARET AS (IST:MEDTR), the current Return-on-Tangible-Equity is -7.47% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is MEDITERA TIBBI MALZEMENAYI VE TICARET AS (IST:MEDTR) Overvalued in 2026?
Based on GuruFocus' analysis, MEDITERA TIBBI MALZEMENAYI VE TICARET AS stock appears to be undervalued.
The current stock price of ₺27.32 is trading 37.8% below its estimated GF Value™ of ₺43.90.
GuruFocus considers MEDITERA TIBBI MALZEMENAYI VE TICARET AS to be Significantly Undervalued.
Key valuation signals for IST:MEDTR:
Return-on-Tangible-Equity: -7.47%
GF Value™: ₺43.90 vs. price of ₺27.32 (37.8% below fair value)
No single metric tells the full story. See the IST:MEDTR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
MEDITERA TIBBI MALZEMENAYI VE TICARET AS Business Description
MEDITERA TIBBI MALZEME SANAYI VE TICARET AS is engaged in the manufacture of anesthesia and intensive care circuits, the installation, operation, and design of oncology drug preparation and delivery systems, production, sales, and technical service of infusion pumps and sets, and the manufacture of biocidal products.
79GF Score
Get the complete analysis for IST:MEDTR
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IST:MEDTR has been successfully added to your 
